Agile Therapeutics,Inc. (NASDAQ:AGRX) Files An 8-K Other Events
Item 8.01Other Events
On December1, 2016, Agile Therapeutics,Inc. (the Company) issued
a press release announcing that it had received net proceeds of
approximately $3 million in non-dilutive financing through the
State of New Jerseys Technology Business Tax Certificate Transfer
Program (the Program). The Program enables approved biotechnology
companies to sell their unused Net Operating Loss Carryovers and
unused Research and Development Tax Credits for at least 80% of
the value of the tax benefits to unaffiliated, profitable
corporate taxpayers in the State of New Jersey. The New Jersey
Economic Development Authority and the New Jersey Department of
the Treasurys Division of Taxation administer the Program. The
Company intends to use the proceeds from the sale for working
capital purposes.
A copy of the press release is furnished as Exhibit99.1 to this
Current Report on Form8-K.
Item 9.01. Financial Statements and
Exhibits.
(d) Exhibits.
|
Exhibit Number |
|
Description |
|
99.1 |
Press release issued by Agile Therapeutics,Inc. dated |
About Agile Therapeutics, Inc. (NASDAQ:AGRX)
Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period. Agile Therapeutics, Inc. (NASDAQ:AGRX) Recent Trading Information
Agile Therapeutics, Inc. (NASDAQ:AGRX) closed its last trading session down -0.01 at 6.87 with 69,998 shares trading hands.
